Edge Therapeutics, Inc. (EDGE) Reaches $1.18 52 Week Low; Shorts at OPSENS COMMON SHARES CANADA (OPSSF) Lowered By 2.88%

March 30, 2018 - By Richard Conner

Edge Therapeutics, Inc. (NASDAQ:EDGE) Logo

OPSENS INC COMMON SHARES CANADA (OTCMKTS:OPSSF) had a decrease of 2.88% in short interest. OPSSF’s SI was 27,000 shares in March as released by FINRA. Its down 2.88% from 27,800 shares previously. With 20,100 avg volume, 1 days are for OPSENS INC COMMON SHARES CANADA (OTCMKTS:OPSSF)’s short sellers to cover OPSSF’s short positions. The SI to OPSENS INC COMMON SHARES CANADA’s float is 0.03%. The stock increased 1.84% or $0.01 during the last trading session, reaching $0.72. About 6,000 shares traded or 4.46% up from the average. Opsens Inc. (OTCMKTS:OPSSF) has 0.00% since March 30, 2017 and is . It has underperformed by 11.55% the S&P500.

The stock of Edge Therapeutics, Inc. (NASDAQ:EDGE) hit a new 52-week low and has $1.14 target or 3.00% below today’s $1.18 share price. The 5 months bearish chart indicates high risk for the $36.43 million company. The 1-year low was reported on Mar, 30 by Barchart.com. If the $1.14 price target is reached, the company will be worth $1.09 million less. The stock decreased 9.92% or $0.13 during the last trading session, reaching $1.18. About 12.10 million shares traded or 1682.08% up from the average. Edge Therapeutics, Inc. (NASDAQ:EDGE) has risen 103.26% since March 30, 2017 and is uptrending. It has outperformed by 91.71% the S&P500.

Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital therapies for acute life-threatening neurological and other conditions. The company has market cap of $36.43 million. The Company’s lead product includes EG-1962, a polymer microsphere used for the treatment of aneurysmal subarachnoid hemorrhage. It currently has negative earnings. The firm is also developing EG-1964 for the management of chronic subdural hematoma as a prophylactic treatment to prevent recurrent bleeding on the surface of the brain.

Among 4 analysts covering Edge Therapeutics (NASDAQ:EDGE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Edge Therapeutics had 5 analyst reports since October 26, 2015 according to SRatingsIntel. Leerink Swann initiated it with “Outperform” rating and $27 target in Monday, October 26 report. The company was initiated on Monday, October 26 by Guggenheim. The rating was initiated by JMP Securities on Monday, October 26 with “Market Outperform”. The rating was maintained by Credit Suisse on Monday, May 9 with “Outperform”. Credit Suisse initiated the stock with “Outperform” rating in Monday, October 26 report.

Opsens Inc. develops, manufactures, installs, and sells fiber optic sensors for interventional cardiology, fractional flow reserve , gas and oil, and industrial applications. The company has market cap of $63.53 million. It operates through two divisions, Medical and Industrial. It currently has negative earnings. The firm primarily focuses on the measure of FFR in interventional cardiology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.